Clinical features and mechanism of liver injury in patients with mild or moderate coronavirus disease 2019
Abstract Background and Aim We aimed to identify clinical features that suggest that coronavirus disease 2019 (COVID‐19) should be a differential diagnosis in patients presenting with a chief complaint of fever and abnormal liver function. Methods We retrospectively studied the presence or absence o...
Main Authors: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-08-01
|
Series: | JGH Open |
Subjects: | |
Online Access: | https://doi.org/10.1002/jgh3.12599 |
id |
doaj-4128aad2df4842f6ab4894700f3eca7a |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kuniyo Gomi Takayoshi Ito Fumihiro Yamaguchi Yoshito Kamio Yoshinori Sato Hiroyoshi Mori Kei Endo Takashi Abe Shunsuke Sakakura Kouji Kobayashi Ken Shimada Jun Noda Tarou Hibiki Shin Ohta Hironori Sagara Akihiko Tanaka Megumi Jinno Masataka Yamawaki Fumiya Nishimoto Kazuaki Inoue Masatsugu Nagahama |
spellingShingle |
Kuniyo Gomi Takayoshi Ito Fumihiro Yamaguchi Yoshito Kamio Yoshinori Sato Hiroyoshi Mori Kei Endo Takashi Abe Shunsuke Sakakura Kouji Kobayashi Ken Shimada Jun Noda Tarou Hibiki Shin Ohta Hironori Sagara Akihiko Tanaka Megumi Jinno Masataka Yamawaki Fumiya Nishimoto Kazuaki Inoue Masatsugu Nagahama Clinical features and mechanism of liver injury in patients with mild or moderate coronavirus disease 2019 JGH Open coronavirus disease 2019 liver injury liver‐infiltrating lymphocytes severe acute respiratory syndrome coronavirus 2 |
author_facet |
Kuniyo Gomi Takayoshi Ito Fumihiro Yamaguchi Yoshito Kamio Yoshinori Sato Hiroyoshi Mori Kei Endo Takashi Abe Shunsuke Sakakura Kouji Kobayashi Ken Shimada Jun Noda Tarou Hibiki Shin Ohta Hironori Sagara Akihiko Tanaka Megumi Jinno Masataka Yamawaki Fumiya Nishimoto Kazuaki Inoue Masatsugu Nagahama |
author_sort |
Kuniyo Gomi |
title |
Clinical features and mechanism of liver injury in patients with mild or moderate coronavirus disease 2019 |
title_short |
Clinical features and mechanism of liver injury in patients with mild or moderate coronavirus disease 2019 |
title_full |
Clinical features and mechanism of liver injury in patients with mild or moderate coronavirus disease 2019 |
title_fullStr |
Clinical features and mechanism of liver injury in patients with mild or moderate coronavirus disease 2019 |
title_full_unstemmed |
Clinical features and mechanism of liver injury in patients with mild or moderate coronavirus disease 2019 |
title_sort |
clinical features and mechanism of liver injury in patients with mild or moderate coronavirus disease 2019 |
publisher |
Wiley |
series |
JGH Open |
issn |
2397-9070 |
publishDate |
2021-08-01 |
description |
Abstract Background and Aim We aimed to identify clinical features that suggest that coronavirus disease 2019 (COVID‐19) should be a differential diagnosis in patients presenting with a chief complaint of fever and abnormal liver function. Methods We retrospectively studied the presence or absence of abnormal liver function in 216 patients diagnosed with mild–moderate severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection between February and September 2020. Results Abnormal liver function was observed in 51 patients with mild–moderate COVID‐19. The median peak aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate dehydrogenase (LDH) levels were 57.5, 75.5, and 332.5 U/L, respectively. The median number of days from symptom onset to peak AST, ALT, and LDH were 8.5, 9, and 8.5, respectively. The median peak LDH/AST ratio was 9.0. Low lymphocyte‐to‐white blood cell ratio and elevated LDH were found to be independent contributing factors for intensive care unit (ICU) admission on a multivariate analysis. Conclusions AST‐predominant AST/ALT/LDH elevation peaking 8–9 days after symptom onset and not accompanied by elevated alkaline phosphatase or gamma‐glutamyl transferase may be a useful clinical feature for differentiating COVID‐19 from other diseases. Since the median LDH/AST ratio was 9.0, it seems that the abnormal liver function caused by SARS‐CoV‐2 is an indirect damage to liver cells due to elevated cytokine levels caused by liver‐infiltrating lymphocytes. SARS‐CoV‐2 infection should be considered in patients presenting with a chief complaint of fever and liver injury; those with a high lymphocyte‐to‐white blood cell ratio or and a high LDH/AST ratio may be admitted to the ICU. |
topic |
coronavirus disease 2019 liver injury liver‐infiltrating lymphocytes severe acute respiratory syndrome coronavirus 2 |
url |
https://doi.org/10.1002/jgh3.12599 |
work_keys_str_mv |
AT kuniyogomi clinicalfeaturesandmechanismofliverinjuryinpatientswithmildormoderatecoronavirusdisease2019 AT takayoshiito clinicalfeaturesandmechanismofliverinjuryinpatientswithmildormoderatecoronavirusdisease2019 AT fumihiroyamaguchi clinicalfeaturesandmechanismofliverinjuryinpatientswithmildormoderatecoronavirusdisease2019 AT yoshitokamio clinicalfeaturesandmechanismofliverinjuryinpatientswithmildormoderatecoronavirusdisease2019 AT yoshinorisato clinicalfeaturesandmechanismofliverinjuryinpatientswithmildormoderatecoronavirusdisease2019 AT hiroyoshimori clinicalfeaturesandmechanismofliverinjuryinpatientswithmildormoderatecoronavirusdisease2019 AT keiendo clinicalfeaturesandmechanismofliverinjuryinpatientswithmildormoderatecoronavirusdisease2019 AT takashiabe clinicalfeaturesandmechanismofliverinjuryinpatientswithmildormoderatecoronavirusdisease2019 AT shunsukesakakura clinicalfeaturesandmechanismofliverinjuryinpatientswithmildormoderatecoronavirusdisease2019 AT koujikobayashi clinicalfeaturesandmechanismofliverinjuryinpatientswithmildormoderatecoronavirusdisease2019 AT kenshimada clinicalfeaturesandmechanismofliverinjuryinpatientswithmildormoderatecoronavirusdisease2019 AT junnoda clinicalfeaturesandmechanismofliverinjuryinpatientswithmildormoderatecoronavirusdisease2019 AT tarouhibiki clinicalfeaturesandmechanismofliverinjuryinpatientswithmildormoderatecoronavirusdisease2019 AT shinohta clinicalfeaturesandmechanismofliverinjuryinpatientswithmildormoderatecoronavirusdisease2019 AT hironorisagara clinicalfeaturesandmechanismofliverinjuryinpatientswithmildormoderatecoronavirusdisease2019 AT akihikotanaka clinicalfeaturesandmechanismofliverinjuryinpatientswithmildormoderatecoronavirusdisease2019 AT megumijinno clinicalfeaturesandmechanismofliverinjuryinpatientswithmildormoderatecoronavirusdisease2019 AT masatakayamawaki clinicalfeaturesandmechanismofliverinjuryinpatientswithmildormoderatecoronavirusdisease2019 AT fumiyanishimoto clinicalfeaturesandmechanismofliverinjuryinpatientswithmildormoderatecoronavirusdisease2019 AT kazuakiinoue clinicalfeaturesandmechanismofliverinjuryinpatientswithmildormoderatecoronavirusdisease2019 AT masatsugunagahama clinicalfeaturesandmechanismofliverinjuryinpatientswithmildormoderatecoronavirusdisease2019 |
_version_ |
1721220272668803072 |
spelling |
doaj-4128aad2df4842f6ab4894700f3eca7a2021-08-05T17:09:12ZengWileyJGH Open2397-90702021-08-015888889510.1002/jgh3.12599Clinical features and mechanism of liver injury in patients with mild or moderate coronavirus disease 2019Kuniyo Gomi0Takayoshi Ito1Fumihiro Yamaguchi2Yoshito Kamio3Yoshinori Sato4Hiroyoshi Mori5Kei Endo6Takashi Abe7Shunsuke Sakakura8Kouji Kobayashi9Ken Shimada10Jun Noda11Tarou Hibiki12Shin Ohta13Hironori Sagara14Akihiko Tanaka15Megumi Jinno16Masataka Yamawaki17Fumiya Nishimoto18Kazuaki Inoue19Masatsugu Nagahama20Division of Gastroenterology, Department of Medicine Showa University Fujigaoka Hospital Yokohama JapanDigestive Disease Center Showa University Koto‐Toyosu Hospital Tokyo JapanDivision of Respiratory and Allergology, Department of Medicine Showa University Fujigaoka Hospital Yokohama JapanDivision of Chest Surgery, Department of Surgery Showa University Fujigaoka Hospital Yokohama JapanDivision of Nephrology, Department of Medicine Showa University Fujigaoka Hospital Yokohama JapanDivision of Cardiology, Department of Medicine Showa University Fujigaoka Hospital Yokohama JapanDivision of Diabetes, Metabolism and Endocrinology, Department of Medicine Showa University Fujigaoka Hospital Yokohama JapanDivision of Respiratory and Allergology, Department of Medicine Showa University Fujigaoka Hospital Yokohama JapanDivision of Respiratory and Allergology, Department of Medicine Showa University Fujigaoka Hospital Yokohama JapanDivision of Medical Oncology, Department of Medicine Showa University Koto‐Toyosu Hospital Tokyo JapanDivision of Medical Oncology, Department of Medicine Showa University Koto‐Toyosu Hospital Tokyo JapanDivision of Gastroenterology International Goodwill Hospital Yokohama JapanDivision of Gastroenterology International Goodwill Hospital Yokohama JapanDivision of Respiratory Medicine and Allergology, Department of Medicine Showa University Hospital Tokyo JapanDivision of Respiratory Medicine and Allergology, Department of Medicine Showa University Hospital Tokyo JapanDivision of Respiratory Medicine and Allergology, Department of Medicine Showa University Hospital Tokyo JapanDivision of Respiratory Medicine and Allergology, Department of Medicine Showa University Hospital Tokyo JapanDivision of Gastroenterology Kikuna Memorial Hospital Yokohama JapanDivision of Gastroenterology Kikuna Memorial Hospital Yokohama JapanDivision of Gastroenterology International University of Health and Welfare Narita Hospital Chiba JapanDivision of Gastroenterology, Department of Medicine Showa University Fujigaoka Hospital Yokohama JapanAbstract Background and Aim We aimed to identify clinical features that suggest that coronavirus disease 2019 (COVID‐19) should be a differential diagnosis in patients presenting with a chief complaint of fever and abnormal liver function. Methods We retrospectively studied the presence or absence of abnormal liver function in 216 patients diagnosed with mild–moderate severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection between February and September 2020. Results Abnormal liver function was observed in 51 patients with mild–moderate COVID‐19. The median peak aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate dehydrogenase (LDH) levels were 57.5, 75.5, and 332.5 U/L, respectively. The median number of days from symptom onset to peak AST, ALT, and LDH were 8.5, 9, and 8.5, respectively. The median peak LDH/AST ratio was 9.0. Low lymphocyte‐to‐white blood cell ratio and elevated LDH were found to be independent contributing factors for intensive care unit (ICU) admission on a multivariate analysis. Conclusions AST‐predominant AST/ALT/LDH elevation peaking 8–9 days after symptom onset and not accompanied by elevated alkaline phosphatase or gamma‐glutamyl transferase may be a useful clinical feature for differentiating COVID‐19 from other diseases. Since the median LDH/AST ratio was 9.0, it seems that the abnormal liver function caused by SARS‐CoV‐2 is an indirect damage to liver cells due to elevated cytokine levels caused by liver‐infiltrating lymphocytes. SARS‐CoV‐2 infection should be considered in patients presenting with a chief complaint of fever and liver injury; those with a high lymphocyte‐to‐white blood cell ratio or and a high LDH/AST ratio may be admitted to the ICU.https://doi.org/10.1002/jgh3.12599coronavirus disease 2019liver injuryliver‐infiltrating lymphocytessevere acute respiratory syndrome coronavirus 2 |